Celladon Corp Stock Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 13.48 | Sales 2023 | 15.77 | Capitalization | 9.96M |
---|---|---|---|---|---|
Net income 2022 | -96M | Net income 2023 | -75M | EV / Sales 2022 | -836,796 x |
Net cash position 2022 | 63.29M | Net Debt 2023 | 15.36M | EV / Sales 2023 | 1,605,487 x |
P/E ratio 2022 |
-0.51
x | P/E ratio 2023 |
-0.13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.21% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |